Търсене на изпитвания

Активни:

Намерени 4,781 изпитвания Стр. 188 от 240

Предстои набиране

Effect of Positive End-Expiratory Pressure Titration on Venous Excess Ultrasound Score and Renal Outcomes in Patients With Acute Respiratory Distress Syndrome

Acute Respiratory Distress Syndrome (ARDS)

This study is a prospective observational cohort study conducted planned to include 40 patients with ARDS to assess the effect of different levels of PEEP titration on VExUS score and renal outcomes in patients with Acute Respiratory Distress Syndrome.

Начало: 12.04.2026 Край: 12.10.2026 Възраст: 18–18 г.

Fayoum University NCT07545252

Предстои набиране

The Effectiveness of Motivational Interviewing in Preventing Early Childhood Caries Among Mothers of Infants in Terengganu.

Healthy Women Caries of Infancy

This study will be conducted in Ministry of Health (MOH) Maternal and Child Health Clinics (MCHCs) and MOH dental clinics in Setiu and Hulu Terengganu, selected for their similar sociodemographic characteristics. A two-arm, parallel cluster-randomized controlled trial (1:1 allocation) will be implemented, where the study group receives Anticipatory Guidance (AG) through Motivational Interviewing (MI), and the control group receives conventional MOH AG. Mothers aged ≥18 years who can understand Bahasa Malaysia and their healthy 6-month-old infants (full-term, without congenital conditions) are eligible. Mothers with postpartum depression and infants requiring special oral healthcare are excluded. A total of 228 mother-infant pairs will be recruited using multistage sampling. Three MCHCs from Setiu and three randomly selected MCHCs from Hulu Terengganu will participate. Systematic sampling will be applied within each clinic. Data collection occurs at infant ages 6, 9, and 12 months during routine immunization visits. At each visit, infants undergo oral examination using ICDAS and a caries risk assessment. Mothers complete age-specific validated questionnaires on knowledge and practices. The study group receives two MI sessions (at 6 and 9 months) with follow-up phone calls, while the control group receives routine AG by MOH staff. The MI protocol will be developed based on established MI frameworks and be validated through expert review, will be pretested among mothers and dental officers/therapists in MOH MCHC and MOH dental clinic in Besut district. While fidelity assessment of MI sessions conducted will be done using MITI 4.2.1 guidelines. All MI sessions will be delivered by the trained principal investigator. Approximately 8 minutes are required for infant oral examination, 7 minutes for questionnaire completion, and 30 minutes for MI. Data will be analysed using descriptive statistics, paired t-tests, independent t-tests, McNemar's test, and Chi-Square test with significance set at p \< 0.05. Ethical approval was obtained from Jawatankuasa Etika Penyelidikan Manusia USM (JEPeM)/ Human Research Ethics Committee USM (HREC) and Medical Research and Ethics Committee (MREC) MOH. Participation is voluntary, with confidentiality ensured. No major risks are expected.

Начало: 12.04.2026 Край: 30.11.2026 Възраст: от 18 г.

Universiti Sains Malaysia NCT07538219

Предстои набиране

Intravascular Ultrasound- and Angiography-Derived Fractional Flow Reserve-Guided Drug-Coated Balloon for Large Coronary Artery De Novo Lesions

Coronary Artery Disease

Trial name Intravascular Ultrasound- and Angiography-Derived Fractional Flow Reserve-Guided Drug-Coated Balloon for Large Coronary Artery De Novo Lesions Objectives To compare the safety and efficacy of Drug-Coated Balloons (DCB) versus Drug-Eluting Stents (DES) in large de novo coronary lesions guided by intravascular ultrasound (IVUS) and Angiography-derived fractional flow reserve (AngioFFR). Study design Investigator-initiated, open-label, multicenter, non-inferiority randomized controlled trial Patient enrollment 2,492 patients enrolled in China and Republic of Korea. Duration Anticipated recruitment is 2 years. Follow-up will be performed at 1, 3, 6, 12, 36, and 60 months. Inclusion Criteria 1. Patients must require PCI based on clinical condition (angiographic stenosis ≥ 75% or angiographic stenosis ≥ 50% with AngioFFR≤0.80) and have signed the informed consent form. 2. Coronary angiography shows a single non-left main lesion, with a reference vessel diameter between 2.75mm and 4.00mm, and an estimated lesion length \< 40mm. 3. Following adequate intraoperative lesion preparation, the following must be met: IVUS shows MLA≥ 4.0mm² and/or AnioFFR \> 0.80. 4. Absence of flow-limiting dissection or hematoma (angiographic Type A or B dissection; IVUS dissection not involving the media) and TIMI flow grade 3 5. Patients must be able to be followed up for more than 1 year and be willing to cooperate with the trial follow-up requirements. Exclusion Criteria 1. Patients are younger than 19 or older than 80 years of age. 2. High-Risk Clinical/Anatomical Factors: Cardiogenic shock, left main disease, severely tortuous lesions, complex bifurcation lesions, severe calcification, total occlusion of the target vessel, or bypass grafts. 3. Recent major surgery (within 1 month pre-procedure) or clear gastrointestinal bleeding events. 4. Known allergy or contraindication to heparin, aspirin, clopidogrel, prasugrel, ticagrelor, or contrast media (patients with clear contrast allergies such as rash may be included if controlled beforehand with effective medication like glucocorticoids or diphenhydramine). 5. Women who are currently pregnant or breastfeeding. 6. Non-cardiac comorbidities indicating an expected life expectancy of less than 1 year. 7. Any other factors that may affect follow-up or participation in other clinical studies. Patient follow-up Clinical follow-up will perform 1, 6, 12, 36 and 60 months after the procedure by telephone contacts or office visits. Primary endpoint The study employs a hierarchical testing (sequential testing) approach, following the logical order below: 1.12-Month Net Adverse Clinical Events (NACE): Defined as a composite endpoint consisting of all-cause death, stroke, myocardial infarction (MI), ischemia-driven revascularization, and bleeding (BARC 3 or 5). 2.Ischemic Endpoint - Major Adverse Cardiac and Cerebrovascular Events (MACCE): Defined as the composite of death, MI, ischemia-driven revascularization, and ischemic stroke. 3.Bleeding Endpoint: Defined as 12-month major bleeding or clinically relevant non-major bleeding, categorized as BARC 2, 3, or 5. Secondary endpoint 1. Target Vessel Failure (TVF): A composite of cardiac death, target vessel MI, or target vessel revascularization. 2. NACE, major bleeding or clinically relevant non-major bleeding, and MACCE at 36 and 60 months. 3. All-cause death and cardiac death. 4. MI, spontaneous MI, peri-procedural MI, and target vessel MI. 5. Any revascularization of the target vessel/target lesion. 6. Any revascularization of a non-target vessel/ non-target lesion. 7. Any revascularization (ischemia-driven or all-cause). 8. Stent Thrombosis: Classified as definite, probable, or possible. 9. Stroke: Including both ischemic and hemorrhagic stroke. 10. Bleeding Events: BARC 3 or 5 bleeding, and BARC 2 bleeding. 11. Evaluation of cost-effectiveness.

Начало: 10.04.2026 Край: 31.05.2033 Възраст: 19–80 г.

Second Affiliated Hospital, School of Medicine, Zhejian NCT07548281

Предстои набиране

Photobiomodulation on Core Symptoms of Autism

Autism

This study aims to evaluate the effectiveness of photobiomodulation therapy on core symptoms in children with autism spectrum disorder. Participants will receive designed physical therapy, occupational therapy and speech program in addition to Photobiomodulation over a defined period. Out comes will be assessed using standardized clinical scales to determine improvements in social interactions, communication and behavior.

Начало: 10.04.2026 Край: 10.08.2026 Възраст: 2–6 г.

Suez University NCT07542899

Предстои набиране

Postoperative Analgesia and Recovery Quality in Total Thyroidectomy

Postoperative Pain

This prospective observational study evaluates the association between postoperative analgesic approaches and recovery outcomes in patients undergoing elective total thyroidectomy. Patients will be followed under routine clinical care without intervention or randomization. The primary outcome is the Quality of Recovery-15 (QoR-15) score at 24 hours. Secondary outcomes include swallowing pain, resting pain, opioid consumption, postoperative nausea and vomiting, and additional analgesic requirement.

Начало: 10.04.2026 Край: 10.09.2026 Възраст: 18–65 г.

Turkey (Türkiye) Istinye University NCT07547124

Предстои набиране

Clinical Validation of an Artificial Intelligence-Based Scoring System for the Modified Rankin Scale (mRS) in Patients With Stroke

Stroke

This study aims to validate the clinical performance of an artificial intelligence (AI)-based automatic scoring system for the Modified Rankin Scale (mRS). The core comparison is the consistency and accuracy between the AI-generated scores and standardized manual mRS follow-up assessments performed by trained professionals. The goal is to provide a convenient, efficient, and objective tool for stroke prognosis assessment, reduce the subjective variability of manual scoring, and optimize the stroke follow-up workflow.

Начало: 10.04.2026 Край: 31.12.2028 Възраст: от 18 г.

Xuanwu Hospital, Beijing NCT07544927

Предстои набиране Фаза 2

Bactericidal Activity of TBD09 in Combination With Other Drugs in Pulmonary Tuberculosis

Drug Susceptible Pulmonary Tuberculosis

The purpose of this study is to evaluate if TBD09 in combination with other active agents in adults with drug sensitive pulmonary tuberculosis has potential to be safe and effective.

Начало: 10.04.2026 Край: 05.11.2026 Възраст: 18–65 г.

South Africa Gates Medical Research Institute NCT07525427

Предстои набиране

Validity and Reliability of the Turkish Version of the 'Breathing Vigilance Questionnaire'

Healthy Adult Participants

In the literature, assessment questionnaires related to dyspnea measure beliefs about breathing-related symptoms but do not directly measure breath awareness. For this purpose, the Breath Vigilance Questionnaire (BVQ) is a subjective questionnaire developed from the Pain Awareness Questionnaire that directly measures breath-specific awareness and includes questions evaluating the interaction between conscious monitoring and control of breathing and anxiety. The questionnaire, consisting of 6 questions, was developed on healthy individuals and its validity and reliability were established. It uses a 5-point Likert scale from 1 (never) to 5 (always), with scores ranging from 6 to 30, and higher scores indicate higher breath awareness . The reliability and validity of the Turkish version of the Breath Vigilance Questionnaire will assist researchers in assessing dysfunctional breathing and developing treatment strategies by evaluating breath awareness. Therefore, the study aimed to investigate the validity and reliability of the Turkish version.

Начало: 10.04.2026 Край: 10.06.2026 Възраст: 18–65 г.

Turkey (Türkiye) Kutahya Health Sciences University NCT07544472

Предстои набиране

Effects of Ultrasound-Guided Scalp Block on Opioid Use, Hemodynamics, and Postoperative Inflammation in Craniotomy

Craniotomy Surgery

This study shows that in craniotomy patients using a skull pin head holder, an ultrasound-guided scalp block reduces perioperative opioid consumption, improves hemodynamic stability, and decreases the inflammatory response.

Начало: 10.04.2026 Край: 10.03.2027 Възраст: от 18 г.

Turkey (Türkiye) Fatih Sultan Mehmet Training and Research Hospital NCT07545655

Предстои набиране Фаза 1/2

ASCERV Study: MRG003 Combined With QL1706 in Recurrent or Metastatic Cervical Cancer

Recurrent or Metastatic Cervical Cancer

This is a single-arm, multicenter, phase II study designed to evaluate the efficacy and safety of MRG003, an anti-EGFR antibody-drug conjugate, in combination with QL1706, a PD-1/CTLA-4 bispecific antibody, in patients with recurrent or metastatic cervical cancer who have failed prior platinum-based therapy.

Начало: 10.04.2026 Край: 31.03.2030 Възраст: от 18 г.

Second Affiliated Hospital, School of Medicine, Zhejian NCT07542717

Предстои набиране Фаза 1/2

A Phase I/Ⅱ Clinical Trial for Umbilical Cord Mesenchymal Stem Cells (UC-MSC) in the Treatment of Ankylosing Spondylitis

Ankylosing Spondylitis

The goal of this clinical trial is to evaluate the safety, tolerability and efficacy of human umbilical cord mesenchymal stem cell injection (HS\_SW01 cells injection) in patients with Ankylosing Spondylitis. Participants will be required to sign the informed consent form and will only be assigned to the study and enrolled after undergoing a series of tests and meeting the inclusion and exclusion criteria of the protocol.

Начало: 10.04.2026 Край: 31.12.2027 Възраст: 18–65 г.

Shenzhen Huishan Biotechnology Co., Ltd. NCT07534644

Предстои набиране Фаза 1/2

Umbilical Cord Mesenchymal Stem Cells (UC-MSC) in the Treatment of Systemic Sclerosis

Systemic Sclerosis (SSc)

The goal of this clinical trial is to evaluate the safety and tolerability of human umbilical cord mesenchymal stem cell injection(HS\_SW01 Cells injection) in patients with systemic sclerosis, and to further explore its pharmacokinetics(PK), immunological profile and preliminary efficacy. Participants will be required to sign the informed consent form and will only be assigned to the study and enrolled after undergoing a series of tests and meeting the inclusion and exclusion criteria of the protocol.

Начало: 10.04.2026 Край: 31.12.2027 Възраст: 18–65 г.

Shenzhen Huishan Biotechnology Co., Ltd. NCT07535931

Предстои набиране

Clinical Validation of an Artificial Intelligence-Based G-FAST Score in Patients With Stroke

Stroke

This study aims to validate the clinical performance of an artificial intelligence (AI)-based automatic assessment system for the G-FAST score. The core comparison is the consistency and accuracy between AI-generated G-FAST results and standardized manual G-FAST assessments performed by trained professionals. The goal is to provide a convenient, efficient, and objective tool for acute stroke screening and early identification, reduce the subjective variability of manual scoring, and optimize the pre-hospital and in-hospital stroke assessment workflow.

Начало: 10.04.2026 Край: 31.12.2028 Възраст: от 18 г.

Xuanwu Hospital, Beijing NCT07538492

Предстои набиране Фаза 1/2

A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC

Advanced or Unresectable Hepatocellular Carcinoma (HCC)

This is a randomized, open-label, multicenter Phase Ib/II registration trial designed to evaluate the efficacy and safety of HH-009 in patients with FGF19-positive hepatocellular carcinoma (HCC). The study will also assess pharmacokinetics, pharmacodynamics, immunogenicity, and exploratory biomarkers. Approximately 30 patients with FGF19-positive advanced HCC will be enrolled. Eligible participants will be randomized 1:1 to receive HH-009 at either 20 mg/kg or 30 mg/kg Q3W as monotherapy. Treatment will continue until disease progression, unacceptable toxicity, initiation of new anticancer therapy, study withdrawal, completion of two years of treatment, loss to follow-up, death, or other protocol-specified reasons, whichever occurs first.

Начало: 10.04.2026 Край: 30.01.2029 Възраст: 18–75 г.

China Huahui Health NCT07547553

Предстои набиране Фаза 2

Low-dose Bevacizumab Plus Adebrelimab Combined With Transarterial Chemoembolization Followed by TACE-HAIC

Adebrelimab (SHR-1316) Bevacizumab Hepatocellular Carcinoma (HCC)

his is a single-arm, phase II clinical study evaluating the efficacy and safety of low-dose bevacizumab (7.5 mg/kg, Q3W) plus adebrelimab (1200 mg, Q3W) combined with transarterial chemoembolization (TACE) followed by hepatic arterial infusion chemotherapy (HAIC) with the FOLFOX regimen as first-line treatment for patients with unresectable hepatocellular carcinoma (HCC). Eligible participants will receive TACE followed by HAIC (oxaliplatin, leucovorin, and fluorouracil) and subsequent intravenous administration of adebrelimab and low-dose bevacizumab every 3 weeks. The primary endpoint is objective response rate (ORR) assessed by investigators per RECIST v1.1. Secondary endpoints include progression-free survival (PFS), disease control rate (DCR), duration of response (DoR), overall survival (OS), and safety. A total of 38 participants will be enrolled using Simon's two-stage optimal design (alpha=0.05, power=0.8). The study is sponsored by the Third Affiliated Hospital of Sun Yat-sen University. Adebrelimab is provided free of charge for two years by Shanghai Shengdi Pharmaceutical Co., Ltd.

Начало: 10.04.2026 Край: 31.08.2029 Възраст: от 18 г.

Third Affiliated Hospital, Sun Yat-Sen University NCT07543783

Предстои набиране

Comparison of the Effectiveness of Myofascial Release Technique and Pilates Exercises in Chronic Non-Specific Low Back Pain

Chronic Non-specific Low Back Pain

Objective: To evaluate the effectiveness of adding Myofascial Release Technique (MRT) to Clinical Pilates in adults with chronic non-specific low back pain (CNSLBP). Hypothesis: MRT combined with Pilates will lead to greater improvements in pain, functional disability, and soft tissue mobility compared to Pilates alone. Design \& Intervention: Randomized controlled trial. Participants (18-45 years) will be randomly assigned to: MRT + Clinical Pilates Clinical Pilates only for 6 weeks (2 sessions/week). Outcomes: Primary: Pain (VAS), ultrasonographic thickness (multifidus \& thoracolumbar fascia) Secondary: Disability (ODI), lumbar mobility, balance Eligibility: Adults with CNSLBP ≥3 months; excluding spinal surgery, rheumatic disease, and pregnancy.

Начало: 10.04.2026 Край: 01.03.2027 Възраст: 18–45 г.

Turkey (Türkiye) Bahçeşehir University NCT07551323

Предстои набиране Фаза 2

CAR-T Combined With ASCT in the Treatment of Relapsed/Refractory Large B-cell Lymphoma With High-risk Factors.

High-risk R/R LBCL

This is a prospective, single-arm, single-center, open-label clinical study, aiming to evaluate the efficacy and safety of CAR-T combined with ASCT in the treatment of relapsed/refractory large B-cell lymphoma with high-risk factors.

Начало: 08.04.2026 Край: 29.02.2028 Възраст: от 18 г.

China Zhejiang Cancer Hospital NCT07538635

Предстои набиране

Laser Acupuncture for Fatigue in Hemodialysis Patients

ESRD (End Stage Renal Disease) Dialysis Fatigue

The goal of this clinical trial is to learn if laser acupuncture (low-level laser therapy) works to treat fatigue and improve quality of life in adults with end-stage renal disease (ESRD) undergoing hemodialysis. It will also learn about how laser acupuncture affects blood circulation and autonomic nervous system balance. The main questions it aims to answer are: 1. Does laser acupuncture reduce the severity of fatigue and its interference with daily life? 2. Can laser acupuncture improve related symptoms such as insomnia, poor appetite, and skin itching? 3. How does laser acupuncture affect objective markers like microcirculation and heart rate variability? Researchers will compare laser acupuncture to a sham treatment (a look-alike procedure using a device that does not emit a laser) to see if laser acupuncture works to treat fatigue. Participants will: 1. Receive laser acupuncture or a sham treatment during their regular hemodialysis sessions 3 times a week for 4 weeks. 2. Have their fatigue and life quality assessed through questionnaires on the first day, at 4 weeks, and at 8 weeks. 3. Undergo non-invasive tests to measure microcirculation, heart rate variability, and pulse waves, and have photos of their tongue taken for Chinese medicine assessment.

Начало: 08.04.2026 Край: 31.08.2027 Възраст: от 18 г.

Taiwan Taipei City Hospital NCT07538310

Предстои набиране Фаза 1/2

BCMA-CD19 cCAR T for the Treatment of Refractory Inflammatory Bowel Disease (IBD)

Inflammatory Bowel Diseases (IBD)

This is a Phase I, IIa, Single-Arm, interventional, open label, treatment study to evaluate the safety and tolerability of ICG318 CAR-T (BCMA-CD19-IL-15/IL15sushi cCAR T cells) in patients with relapsed and/or refractory inflammatory bowel disease.

Начало: 07.04.2026 Край: 07.04.2028 Възраст: 18–70 г.

China iCell Gene Therapeutics NCT07544160

Предстои набиране

Music Therapy for Comatose Brain Injured Patients

Traumatic Brain Injury

The goal of this single-arm observational study is to determine whether alpha music therapy, initiated early in the recovery period, can improve cognitive function for severe traumatic brain injury patients when compared to historic controls. Participants will listen to selected music through headphones. The investigators will compare cognitive function between groups at three time points: ICU discharge, hospital discharge, and three months after injury.

Начало: 07.04.2026 Край: 07.04.2028 Възраст: от 18 г.

United States Mercy Health Ohio NCT07544602

1 … 186 187 188 189 190 … 240